Didanosine is a reverse transcriptase inhibitor used to treat HIV. A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen.
- Mechanism
- Curator reviewed
Didanosine (ddI) is metabolized intracellularly by a series of cellular enzymes to its active moiety, dideoxyadenosine triphosphate (ddATP), which inhibits the HIV reverse transcriptase enzyme competitively by competing with natural dATP. It also acts as a chain terminator by its incorporation into viral DNA as the lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated.
- Primary indication
- For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults.Curator reviewed · 1 structured indication
- Formula / weight
- C10H12N4O3 · 236.2273 g/mol (avg)
- First approval
- Canada, 2001 · United States, 1991
- Also known as
- 2,3-Dideoxyinosine · 2',3'-dideoxyinosine · ddIno · Dideoxyinosine
- Code names
- BMY-40900
Resolves to
BXZVVICBKDXVGW-NKWVEPMBSA-NSMILESOC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=OWhat you can answer from here — as of September 30, 2026
Which drugs share a target with Didanosine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account